Loading...
•
Mar 31
•/
QIAGEN Q1 2025 Earnings Report
QIAGEN exceeded its Q1 2025 outlook with strong net sales and earnings growth.
Key Takeaways
QIAGEN delivered a strong Q1 2025 performance with $483 million in revenue, 7% constant currency growth, and $0.55 adjusted EPS, surpassing guidance. Operating margins improved and a dividend initiation along with a $500M share repurchase program were announced.
Net sales reached $483 million, up 5% year-over-year and 7% at constant exchange rates.
Adjusted EPS was $0.55, above the guidance of at least $0.50.
Operating cash flow rose to $140 million, up from $133 million a year ago.
Company proposed initiating a dividend and a new $500 million share repurchase program.
QIAGEN
QIAGEN
Forward Guidance
QIAGEN reaffirmed its 2025 full-year guidance of ~4% CER sales growth and ~$2.35 adjusted EPS, with an improved margin outlook.
Positive Outlook
- Sales and EPS outlooks for FY2025 reaffirmed following strong Q1.
- Core sales expected to grow ~5% at constant exchange rates.
- Adj. EPS outlook reaffirmed at ~$2.35 CER.
- Operating margin target for 2025 set above 30%.
- On track to reach 31% mid-term margin goal earlier than 2028.
Challenges Ahead
- Global macroeconomic uncertainty including tariff pressures.
- Currency fluctuation risks remain present.
- No increase in full-year sales or EPS outlook despite strong Q1.
- Unspecified risks around discontinued product lines.
- Competitive pressures and product integration remain a challenge.